News & Events about Pulmonx Corp.
Pulmonx Co. (NASDAQ:LUNG Get Rating) has earned a consensus rating of Hold from the seven analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and ...
Pulmonx (NASDAQ:LUNG Get Rating) had its price objective lowered by Morgan Stanley from $14.00 to $9.50 in a report issued on Friday, Benzinga reports. The firm currently has an equal weight rating on the stock. Morgan Stanleys price target points to a potential upside ...
Globe Newswire
3 months ago
REDWOOD CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York. Pulmonx management is ...
Business Wire
5 months ago
Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society (ERS) International Conference. Data on the first 40 patients in the...
Ticker Report
6 months ago
Pulmonx (NASDAQ:LUNG Get Rating) had its price target cut by Canaccord Genuity Group from $34.00 to $31.00 in a report issued on Thursday, The Fly reports. They currently have a buy rating on the stock. LUNG has been the topic of several other research reports. Morgan Stanley boosted their ...